The DOI matches its Crossref record; 225 of the 225 references it cites were found in a registry or an index.
Mitochondrial Dysfunction and Biogenesis in Neurodegenerative diseases: Pathogenesis and Treatment
Open accessAbstract
Summary: Neurodegenerative diseases are a heterogeneous group of disorders that are incurable and characterized by the progressive degeneration of the function and structure of the central nervous system (CNS) for reasons that are not yet understood. Neurodegeneration is the umbrella term for the progressive death of nerve cells and loss of brain tissue. Because of their high energy requirements, neurons are especially vulnerable to injury and death from dysfunctional mitochondria. Widespread damage to mitochondria causes cells to die because they can no longer produce enough energy. Several lines of pathological and physiological evidence reveal that impaired mitochondrial function and dynamics play crucial roles in aging and pathogenesis of neurodegenerative diseases. As mitochondria are the major intracellular organelles that regulate both cell survival and death, they are highly considered as a potential target for pharmacological‐based therapies. The purpose of this review was to present the current status of our knowledge and understanding of the involvement of mitochondrial dysfunction in pathogenesis of neurodegenerative diseases including Alzheimer's disease (AD), Parkinson's disease (PD), Huntington's disease (HD), and amyotrophic lateral sclerosis (ALS) and the importance of mitochondrial biogenesis as a potential novel therapeutic target for their treatment. Likewise, we highlight a concise overview of the key roles of mitochondrial electron transport chain (ETC.) complexes as well as mitochondrial biogenesis regulators regarding those diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
2 retracted
Items 201–225 of 225
Mitochondrial transcription factor A variants and the risk of Parkinson's disease
Gawęda-Walerych, K., Safranow, K., Maruszak, A., Białecka, M. A., Kłodowska-Duda, G. A., Czyźewski, K., Sławek, J. W., Rudzińska, M., Styczyńska, M., Opala, G., et al. (2009) · Neuroscience Letters · doi:10.1016/j.neulet.2009.11.037 · Cited by 51
Bahadorani, S., Mukai, S. T., Rabie, J., Beckman, J. S., Phillips, J. P., & Hilliker, A. J. (2013) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2013.03.024 · Cited by 49
d’Abramo, C., Ricciarelli, R., Pronzato, M. A., & Davies, P. (2006) · Journal of Neurochemistry · doi:10.1111/j.1471-4159.2006.03931.x · Cited by 46
Puranam, K. L., Wu, G., Strittmatter, W. J., & Burke, J. R. (2006) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.01.007 · Cited by 44
Braun, R. J. (2012) · Frontiers in Oncology · doi:10.3389/fonc.2012.00182 · Cited by 44
Ortega‐Arellano, H. F., Jiménez-Del-Río, M., & Velez‐Pardo, C. (2011) · Neurochemical Research · doi:10.1007/s11064-011-0451-0 · Cited by 43
Prospects for Neuroprotective Therapies in Prodromal Huntington's disease
Chandra, A., Johri, A., & Beal, M. F. (2014) · Movement Disorders · doi:10.1002/mds.25835 · Cited by 41
The dysfunction of hepatic transcriptional factors in mice with Huntington's Disease
Chiang, M., Chern, Y., & Juo, C. (2011) · Biochimica et Biophysica Acta (BBA) - Molecular Basis of Disease · doi:10.1016/j.bbadis.2011.05.006 · Cited by 41
Lee, J.-H., Kannagi, M., Ferrante, R. J., Kowall, N. W., & Ryu, H. (2009) · The FASEB Journal · doi:10.1096/fj.08-121046 · Cited by 41
Krüger, J., Hinttala, R., Majamaa, K., & Remes, A. M. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-8 · Cited by 39
Zhang, Q., Yu, J., Wang, P., Chen, W., Wu, Z., Jiang, H. F., & Tan, L. (2010) · Brain Research · doi:10.1016/j.brainres.2010.10.074 · Cited by 36
Kilbride, S. M., Gluchowska, S. A., Telford, J. E., O'Sullivan, C., & Davey, G. P. (2011) · Molecular Neurodegeneration · doi:10.1186/1750-1326-6-53 · Cited by 36
Modeling early Parkinson's disease pathology with chronic low dose MPTP treatment
Korecka, J. A., Eggers, R., Swaab, D. F., Bossers, K., & Verhaagen, J. (2013) · Restorative Neurology and Neuroscience · doi:10.3233/rnn-110222 · Cited by 34
Wenz, T., Wang, X., Marini, M., & Moraes, C. T. (2010) · Journal of Cellular and Molecular Medicine · doi:10.1111/j.1582-4934.2010.01223.x · Cited by 33
Cronin-Furman, E. N., Borland, M., Bergquist, K. E., Bennett, J. P., & Trimmer, P. A. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-6 · Cited by 30
Mitochondria morphology and DNA content upon sublethal exposure to beta-amyloid(1-42) peptide.
Diana, A., Šimić, G., Sinforiani, E., Orrù, N., Pichiri, G., & Bono, G. G. (2008) · PubMed · Cited by 28
Imam, M. U., Ismail, M., Ithnin, H., Tubesha, Z., & Omar, A. R. (2013) · Nutrients · doi:10.3390/nu5020468 · Cited by 28
Preconditioning as a Potential Strategy for the Prevention of Parkinson’s Disease
Golpich, M., Rahmani, B., Ibrahim, N. M., Dargahi, L., Mohamed, Z., Raymond, A. A., & Ahmadiani, A. (2014) · Molecular Neurobiology · doi:10.1007/s12035-014-8689-6 · Cited by 26
Self-citationDeArmond, S. J., & Bajsarowicz, K. (2010) · Molecular Neurodegeneration · doi:10.1186/1750-1326-5-6 · Cited by 25
LRRK2 P755L variant in sporadic Parkinson’s disease
Tomiyama, H., Mizuta, I., Li, Y., Funayama, M., Yoshino, H., Li, L., Murata, M., Yamamoto, M., Kubo, S., Mizuno, Y., et al. (2008) · Journal of Human Genetics · doi:10.1007/s10038-008-0336-5 · Cited by 21
Regulation of dynamic BACE1 trafficking in neurons
Buggia-Prévot, V., Fernandez, C., Riordan, S. M., Vetrivel, K. S., Udayar, V., Elie, A., Lefkow, M., Roseman, J., Meckler, X., Bhattacharyya, S., et al. (2013) · Molecular Neurodegeneration · doi:10.1186/1750-1326-8-s1-o8 · Cited by 10
The Cascade of Oxidative Stress and Tau Protein Autophagic Dysfunction in Alzheimer’s Disease
Liu, Z., Li, P., Wu, J., Wang, Y., Li, P., Hou, X., Zhang, Q., Wei, N., Zhao, Z., Liang, H., et al. (2015) · InTech eBooks · doi:10.5772/59980 · Cited by 9
Chaos in heterogeneous neural networks: I. The critical transition point
Aljadeff, J., Stern, M., & Sharpee, T. O. (2014) · BMC Neuroscience · doi:10.1186/1471-2202-15-s1-o20 · Cited by 4
Cell-Permeable, Mitochondrial-Targeted, Peptide Antioxidants
Szeto, H. H. (2008) · Springer eBooks · doi:10.1007/978-0-387-76678-2_31 · Cited by 4
Mitochondrial Respiratory Chain Complex II
Ganesh, J., Wong, L. C., & Gorman, E. B. (2012) · Springer eBooks · doi:10.1007/978-1-4614-3722-2_13 · Cited by 2
Cited by
Spinal Cord Injury: Pathophysiology, Multimolecular Interactions, and Underlying Recovery Mechanisms
Anjum, A., Yazid, M. D., Fauzi Daud, M., Idris, J., Ng, A. M. H., Selvi Naicker, A., Ismail, O. H. R., Athi Kumar, R. K., & Lokanathan, Y. (2020) · International Journal of Molecular Sciences · doi:10.3390/ijms21207533 · Cited by 1,270
Park, M. W., Cha, H. W., Kim, J., Kim, J. H., Yang, H., Yoon, S., Boonpraman, N., Yi, S. S., Yoo, I. D., & Moon, J.-S. (2021) · Redox Biology · doi:10.1016/j.redox.2021.101947 · Cited by 683
Acylcarnitines: Nomenclature, Biomarkers, Therapeutic Potential, Drug Targets, and Clinical Trials
Dambrova, M., Makrecka-Kuka, M., Kuka, J., Vilskersts, R., Nordberg, D., Attwood, M. M., Smesny, S., Sen, Z. D., Guo, A. C., Oler, E., et al. (2022) · Pharmacological Reviews · doi:10.1124/pharmrev.121.000408 · Cited by 507
The Peroxisome-Mitochondria Connection: How and Why?
Fransen, M., Lismont, C., & Walton, P. (2017) · International Journal of Molecular Sciences · doi:10.3390/ijms18061126 · Cited by 351
“Mutations in proteins impairing peroxisome or mitochondrial biogenesis and/or function have been shown to lead to inherited disorders with different, and severe, phenotypic presentations [8,155].”
BackgroundShared molecular and cellular mechanisms of premature ageing and ageing-associated diseases
Kubben, N., & Misteli, T. (2017) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.68 · Cited by 320
Metadata
- Authors
- Golpich, M., Amini, E., Mohamed, Z., Azman Ali, R., Mohamed Ibrahim, N., & Ahmadiani, A.
- Venue
- CNS Neuroscience & Therapeutics
- Publisher
- Wiley
- Published
- 2016-11-22
- Volume
- 23
- Issue
- 1
- Pages
- 5-22
- ISSN
- 1755-5930 (ISSN-L)
- 1755-5949
- OpenAlex
- W2555953028
- Cited by
- 532
- References
- 225
- FWCI
- 15.50
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.